The Commission has approved the acquisition of Pfizer's consumer healthcare business by J&J, subject to conditions. J&J is a leading healthcare group active worldwide in pharmaceuticals, consumer products and medical devices and diagnostics. Pfizer is active in over-the-counter pharmaceuticals and personal care products. The Commission found that the initial transaction would give rise to antitrust concerns in three markets – namely, the Italian market for topical dermatological antifungals, the Greek market for daily-use mouthwash, and the EEA market for nicotine replacement therapy (NRT) products. To address these concerns, J&J offered to divest the overlapping activities in Italy and Greece, and to remove the vertical relationship between J&J's nicotine patch manufacturing activities and Pfizer’s NRT business. The Commission has cleared the acquisition by the Finnish company Metso Corporation Oy (Metso) of the pulp and power business of the Norwegian group Aker Kvaerner ASA. Both companies are active worldwide in the development and production of equipment for pulp mills. In order to address their competitive overlap and the potential for harm to competition in markets for pulp mill equipment, Metso offered to divest its overlapping businesses to a Canada-based company, GL&V.